Fcpm III Services B.V.
NAARDEN, P7
$750m in 11 US stocks at the end of 30 June 2026. The top 10 are 99.9% of the money. It changed about 11.3% of the portfolio this quarter.
Value
$750m
Stocks
11
Top 10 share
99.9%
Turnover
11.3%
What changed this quarter
New
Bought for the first time this quarter.
- Aura BiosciencesAURA3.8% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- NewAmsterdam PharmaNAMS38.3% of the fund-8%
- Dyne TherapeuticsDYN11.4% of the fund-17%
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Damora Therapeutics
- Share
- 8.5%
- Value
- $63m
- Shares
- 2,441,000
Held
- Engene Holdings
- Share
- 2.2%
- Value
- $17m
- Shares
- 9,632,561
Held
- Bicycle TherapeuticsBCYC
- Share
- 2.0%
- Value
- $15m
- Shares
- 3,468,430
Held
- Engene HoldingsENGNW
- Share
- 0.1%
- Value
- $834,376
- Shares
- 2,878,148
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| NewAmsterdam PharmaNAMS | 38.3% | $288m | 8,490,353 | -8% |
| MapLight TherapeuticsMPLT | 15.4% | $116m | 3,226,400 | Held |
| Dyne TherapeuticsDYN | 11.4% | $85m | 3,848,256 | -17% |
| Vor BiopharmaVOR | 10.1% | $76m | 4,117,354 | Held |
| Damora Therapeutics | 8.5% | $63m | 2,441,000 | Held |
| Replimune GroupREPL | 4.1% | $31m | 2,808,368 | Held |
| Crescent BiopharmaCBIO | 4.0% | $30m | 1,677,852 | Held |
| Aura BiosciencesAURA | 3.8% | $29m | 4,053,775 | New |
| Engene Holdings | 2.2% | $17m | 9,632,561 | Held |
| Bicycle TherapeuticsBCYC | 2.0% | $15m | 3,468,430 | Held |
| Engene HoldingsENGNW | 0.1% | $834,376 | 2,878,148 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 103.3% since 30 June 2025.
Where the money is
Health care87.2%
Other12.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.